Riskpilot← Back to searchSign inGet full accessPharMaMacometrics AB
ABActiveOrg 5590385158Villes Väg 8Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
-1% vs 2023
Equity ratio
99.4%
Financial strength
Net profit 2024
SEK 137K
-15% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -10K | -1% |
| Net profit | SEK 137K | -15% |
| Total assets | SEK 6,2M | -1% |
| Equity | SEK 6,2M | -1% |
| Employees | 0 | — |
Legal name
PharMaMacometrics AB
Org number
5590385158
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2 december 2015
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska äga och förvalta aktier i dotter- och intressebolag, förvalta värdepapper och fast och lös egendom, direkt eller indirekt bedriva konsult- och analystjänster inom läkemedels- och bioteknikbranschen, utveckling av modeller och programvara för samma område samt därmed förenlig verksamhet. Bolaget ska även bedriva försäljning av konst producerad inom företaget och relaterad kursverksamhet.
Address
Villes Väg 8
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −12 | −13 | −11 | −9 | −10 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −12 | −13 | −11 | −9 | −10 |
| Net financials | 90 | 97 | 159 | 211 | 182 |
| Profit before tax | 79 | 84 | — | — | — |
| Tax | −17 | −18 | −31 | −42 | −36 |
| Net profit | 62 | 66 | 118 | 160 | 137 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 864 | 6 356 | 6 298 | 6 286 | 6 209 |
| Equity | 6 462 | 6 344 | 6 274 | 6 239 | 6 171 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 402 | 12 | 23 | 46 | 38 |
| Total debt | 402 | 12 | 23 | 46 | 38 |
EBITDA margin
-953100.0%
This company
15.8%
Market median
-6032378% vs market
20202024
Equity ratio
99.4%
This company
38.2%
Market median
+160% vs market
20202024
Return on equity
2.2%
This company
18.4%
Market median
-88% vs market
20202024
Net profit margin
13674500.0%
This company
8.1%
Market median
+168820888% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PharMaMacometrics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Monika Magnusson | Deputy Board Member | 0 companies |
| Mats Oscar Magnusson | Board of Directors | 0 companies |